COMMON INITIAL DOSING REGIMENS

• A typical starting dose is 10–25 mg taken orally once daily, usually at bedtime to mimic the natural nocturnal peak in GH secretion. Higher doses (up to 50 mg daily) may be prescribed based on individual goals and tolerability, particularly in athletic or recovery contexts.

MECHANISM OF ACTION

• Ibutamoren is a selective agonist of the ghrelin receptor (growth hormone secretagogue receptor, GHSR). By stimulating GHSR, it promotes the release of GH from the pituitary gland, which subsequently raises circulating IGF-1 levels. This dual effect enhances protein synthesis, supports muscle and tissue repair, and improves metabolism. Unlike direct GH administration, ibutamoren does not suppress endogenous GH production, allowing for sustained physiological effects.

• A unique feature of ibutamoren is its stimulation of appetite due to ghrelin receptor activation, which may be beneficial for patients with cachexia but potentially undesirable for those focusing on weight management.

COMMON SIDE EFFECTS

• Metabolic: Increased appetite and mild weight gain, which may be advantageous or a drawback depending on therapeutic goals. Transient hyperglycemia or insulin resistance can occur with prolonged use.

• Neurological: Vivid dreams, drowsiness, or mild lethargy.

• Fluid Retention: Peripheral edema, particularly in the lower extremities, is relatively common and dose-dependent.

• Musculoskeletal: Joint pain or stiffness may occur, especially in older adults.

• Severe Effects: Long-term use may potentially exacerbate latent diabetes or increase the risk of metabolic syndrome. Monitoring is crucial for at-risk patients.

CONTRAINDICATIONS

• Absolute: Known hypersensitivity to ibutamoren or its components.

• Relative: Ibutamoren should be used cautiously in individuals with diabetes, insulin resistance, or significant cardiovascular conditions due to its effects on glucose metabolism and potential fluid retention. Patients with a history of cancer should consult their physician, as prolonged GH elevation could theoretically stimulate tumor growth.

COMPARISON WITH OTHER HGH SUPPORT MEDICATIONS

• Ibutamoren vs. CJC-1295: Ibutamoren’s oral administration provides convenience over CJC-1295’s subcutaneous route. However, CJC-1295 offers more sustained GH release and is less likely to cause appetite stimulation, making it preferable for fat loss and long-term GH optimization.

• Ibutamoren vs. Ipamorelin: Ibutamoren’s mechanism of action involves ghrelin receptor activation, leading to increased appetite, while ipamorelin stimulates GH release without appetite effects. Ipamorelin is more suitable for patients who wish to avoid weight gain or glucose dysregulation.

• Ibutamoren vs. Sermorelin: Sermorelin requires daily subcutaneous injections, whereas ibutamoren is taken orally. Sermorelin’s effects are more localized to GH release, while ibutamoren provides broader metabolic impacts through IGF-1 elevation.

• Ibutamoren vs. Tesamorelin: Tesamorelin’s effects are highly targeted toward reducing visceral adiposity and improving lipid profiles, whereas ibutamoren has a more systemic impact on body composition and recovery.

MORE INFORMATION

• FDA Safety Data Sheet not available

• Sinha DK. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 [PubMed Link]

• Sigalos J. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018 [PubMed Link]

• Liu H. Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nat Commun. 2021 [PubMed Link]

• Murphy MG. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998 [PubMed Link]

• Cardaci TD. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Exp Physiol. 2022 [PubMed Link]

• Patchett AA. Orally active growth hormone secretagogues. Pharm Biotechnol. 1998 [PubMed Link] 

• Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005 [PubMed Link]

• Svensson J. Growth hormone secretagogues as therapeutic agents. Growth Horm IGF Res. 1999 [PubMed Link]

• Robinson IC. Hypothalamic targets for growth hormone secretagogues. Acta Paediatr Suppl. 1997 [PubMed Link]

• Micic D. Growth hormone secretagogues: the clinical future. Horm Res. 1999 [PubMed Link]

• Ghigo E. Endocrine and non-endocrine activities of growth hormone secretagogues in humans. Horm Res. 1999 [PubMed Link]

• Smith RG. Growth hormone releasing substances: types and their receptors. Horm Res. 1999 [PubMed Link]

• Svensson JA. Clinical and experimental effects of growth hormone secretagogues on various organ systems. Horm Res. 1999 [PubMed Link]

• Smith RG. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997 [PubMed Link]

• Fuh VL. Growth hormone secretagogues: mechanism of action and use in aging. Growth Horm IGF Res. 1998 [PubMed Link]

• Gaugg M. Rejuvenation in older adults receiving oral ghrelin. Ann Intern Med. 2009 [PubMed Link]

• Papotti M. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. 2000 [PubMed Link]

• Copinschi G. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997 [PubMed Link]

• Patchett AAl. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 [PubMed Link]

• Nass R. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008 [PubMed Link]